Pharmacokinetics and pharmacodynamics of monoclonal antibodies: Concepts and lessons for drug development

BioDrugs

Volumn 24, Issue 1, 2010, Pages 23-39

  Mould, Diane R ^a   Green, Bruce ^a,b  

^a Projections Research Inc   (United States)

^b Model Answers Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABCIXIMAB; ABX 10241; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY STRUCTURE; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; FLUORESCENCE ACTIVATED CELL SORTING; FOOD AND DRUG ADMINISTRATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOGENICITY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE MYELOMA; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RABBIT; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ABSORPTION; ANIMALS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; RECEPTORS, IMMUNOLOGIC; TISSUE DISTRIBUTION;

EID: 75149145545     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11530560-000000000-00000     Document Type: Review

References (117)

1. Abbas AK, Lichtman AH. In: Cellular and molecular immunity. 5th ed. Philadelphia (PA): Elsevier, 2003: 43-53
2. Morell A, Skvaril F, Hitzig WH, et al. Serum concentrations of IgG subclasses. In: Bach FH, Good RA, editors. Clinical immunobiology. Academic Press, 1976: 37-56
3. Galluppi GR, Rogge MC, Roskos LK, et al. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 2001; 69: 387-399
4. Cox DS, Kleinman NS, Boyle DA, et al. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention. J Clin Pharmacol 2004; 44 (9): 981-990
5. ReoPro®.Abciximab: for intravenous administration [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiolo gicApplications/ucm107731.pdf [Accessed 2009 Sep 4]
6. Mahmood I, Green MD, Fisher JE. Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J Clin Pharm 2003; 43 (7): 692-697
7. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): BLA 125118/000 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatf da-docs/nda/2005/ 125118-S0000-BioPharmR.pdf [Accessed 2009 Sep 4]
8. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25 (6): 1700-1721
9. Food and Drug Administration, Centre for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): 125057/0 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/How DrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologic Applications/ucm092770.pdf [Accessed 2009 Sep 4]
10. Food and Drug Administration. Clinical pharmacology review of alefacept [online]. Available from URL: http://www.fda.gov/downloads/Drugs/De velopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approv alApplications/TherapeuticBiologicApplications/ucm086010.pdf [Accessed 2009 Sep 4]
11. Mould DR, Baumann A, Kuhlmann J, et al. Population pharmacokineticspharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukemia. Br J Clin Pharmacol 2007; 64 (3): 278-291
12. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): 103948/0 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2000/103948-0000-Campath-ClinPharm.pdf [Accessed 2009 Sep 4]
13. Food and Drug Administration. Clinical pharmacology review of BLA 97-1251 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/Devel opmentApprovalProcess/HowDrugsareDevelopedandApproved/Approval Applications/TherapeuticBiologicApplications/ucm113364.pdf [Accessed 2009 Sep 4]
14. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): STN-125085/0 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2004/STN-125085-Avastin-BioPharmr.pdf [Accessed 2009 Oct 23]
15. Dirks NL, Nolting A, Kovar A, et al. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol 2008; 48 (3): 267-278
16. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): STN/BLA 125084 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatf da-docs/bla/2004/ 125084-ERBITUX-BIOPHARMR.PDF [Accessed 2009 Oct 23]
17. Food and Drug Administration. Clinical pharmacology review of BLA 97-0736 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/App rovalApplications/TherapeuticBiologicApplications/ucm113472.pdf [Accessed 2009 Oct 23]
18. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): 125166 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2007/125166s0000-PharmcometricsR.pdf [Accessed 2009 Oct 23]
19. Bauer RJ, Russel DL, White RL, et al. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 1999; 27: 397-420
20. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): STN/BLA 125075/0 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatf da-docs/nda/2003/ 125075-0000-Raptiva-BioPharmr.pdf [Accessed 2009 Oct 23]
21. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): STN-125085/0 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/De velopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approval Applications/TherapeuticBiologicApplications/ucm088681.pdf [Accessed 2009 Oct 23]
22. Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001; 41 (11): 1206-1214
23. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): NDA 21174 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/ nda/2000/21174-MYLOTARG-biopharmr.pdf [Accessed 2009 Oct 23]
24. Xu Z,Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an antitumor necrosis factor-{alpha} humanmonoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol 2009 Sep; 49 (9): 1056-1070
25. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): 125289 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2009/125289s000-ClinPharmR-P1.pdf [Accessed 2009 Oct 23]
26. Food and Drug Administration. Zevalin® (ibritumomab tiuxetan) prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/ drugsatfda-docs/label/2009/125019s0156.pdf [Accessed 2009 Oct 23]
27. Food and Drug Administration. Clinical pharmacology review of BLA 98-10012, cA2 [online]. Available from URL: http://www.fda.gov/downloads/ Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/TherapeuticBiologicApplications/ucm107704.pdf [Accessed 2009 Oct 23]
28. Ortho Biotech Products and Services. Orthoclone OKT 3 sterile solution (muromonab-CD3) prescribing information [online]. Available from URL: http://www.orthobiotech.com/orthobiotech/shared/OBI/PI/OKT3-PI.pdf [Accessed 2009 Oct 23]
29. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): 125104 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2004/125104s000-Natalizumab-Biopharmr.pdf [Accessed 2009 Oct 23]
30. Food and Drug Administration. XOLAIR® (Omalizumab) prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugs atfda-docs/label/2007/103976s5102lbl.pdf [Accessed 2009 Oct 23]
31. Food and Drug Administration. SYNAGIS® (palivizumab) patient information [online]. Available from URL: http://www.accessdata.fda.gov/drugs atfda-docs/label/2009/103770s5116lbl.pdf [Accessed 2009 Oct 23]
32. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): 125147/0 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2006/125147s0000-ClinPharmR.pdf [Accessed 2009 Oct 23]
33. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): 125156 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2006/125156s0000-Lucentis-ClinPharmR.pdf [Accessed 2009 Oct 23]
34. Food and Drug Administration. Rituxan® (rituximab) prescribing information [online]. Available from URL: http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/App rovalApplications/TherapeuticBiologicApplications/ucm107741.pdf [Accessed 2009 Oct 23]
35. Food and Drug Administration, Centre for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s): 125011 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2003/125011s000-ClinPharmR.pdf [Accessed 2009 Oct 23]
36. Food and Drug Administration. Clinical pharmacology review of herceptin, 98-0369 [online]. Available from URL: http://www.fda.gov/downloads/ Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/TherapeuticBiologicApplications/ucm091373.pdf [Accessed 2009 Oct 23]
37. Zhu Y, Chuanpu H, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a humanmonoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009; 49: 162-175
38. Edelman GM. Antibody structure and molecular immunology. Science 1973; 180 (4088): 830-840
39. Roskos LK, Davis CG, Schwab GM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res 2004; 61: 108-120
40. Davies J, Jiang L, Pan LZ, et al. Expression of GnTIII in a recombinant anti- CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase inADCCthrough higher affinity for FCgamma RIII. Biotechnol Bioeng 2001; 74: 288-294
41. Spiegelberg HL, Weigle WO. The catabolism of homologous and heterologous 7s gamma globulin fragments. J Exp Med 1965; 121: 323-338
42. Ein D, Waldmann TA. Metabolic studies of a heavy chain disease protein. J Immunol 1969; 103: 345-348
43. Yeung YA, Leabman MK, Marvin JS, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182 (12): 7663-7671
44. Brambell FWR, Halliday R, Morris IG. Interference by human and bovine serum and serum protein fractions with the absorption of antibodies by suckling rats and mice [abstract]. Proc R Soc B 1958; 149: 1
45. Brambell FWR, Hemmings WA, Morris IG. Theoretical model of g-globulin catabolism. Nature 1964; 203: 1352-1355
46. Junghans RP. Finally! The Brambell receptor (FcRB): mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 1997; 16: 29-57
47. Zhu X, Meng G, Dickinson BL, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol 2001; 166 (5): 3266-3276
48. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49: 673-680
49. Marks J. Antibody formation in myelomatosis. J Clin Pathol 1953; 6 (1): 62-63
50. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; I: 1228-1231
51. Jin F, Balthasar JP. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Hum Immunol 2005; 66 (4): 403-410
52. Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001; 98: 3136-3142
53. Tabrizi MA, Tsengb C-ML, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11(1-2): 81-88
54. Cohen-Solal JF, Cassard L, Fridman W-H, et al. Fc gamma receptors. Immunol Lett 2004; 92: 199-205
55. Rascu A, Repp R, Westerdaal NA, et al. Clinical relevance of Fc gamma receptor polymorphisms. Ann N Y Acad Sci 1997; 815: 282-295
56. Reddy MP, Kinney CA, Chaikin MA, et al. Elimination of Fc receptordependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol 2000; 164 (4): 1925-1933
57. Mould DR. Using pharmacometrics in the development of biological therapeutic biological agents. In: Ette E, Williams P, editors. Pharmacometrics: the science of quantitative pharmacology. Hoboken (NJ): John Wiley and Sons, 2007
58. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13: 1-110
59. Wileman T, Harding C, Stahl P. Receptor-mediated endocytosis. Biochem J 1985; 232: 1-14
60. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93 (11): 2645-2668
61. Henry MD, Wen S, Silva MD, et al. A prostate-specific membrane antigentargeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004; 64 (21): 7995-8001
62. Weiner LM. Monoclonal antibody therapy of cancer. Semin Oncol 1999; 26: 43-51
63. Limas CJ, Hasikidis C, Iakovou J, et al. Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Eur J Clin Invest 2003; 33 (6): 443-448
64. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graftversus- host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84 (4): 1320-1327
65. Mould DR, Nieforth KA. Population pharmacokinetic/pharmacodynamic analysis of Zenapax™: some practical considerations in the development of protein pharmaceuticals. Philadelphia (PA): Mid-Atlantic NONMEM Users' Group, 1995
66. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti interleukin-2 receptor antibody in renal transplantation. Transplantation 1997; 63 (1) 1-5
67. Modi NB. Recombinant thrombolytic agents. In: Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical biotechnology: fundamentals and applications. 3rd ed. New York (NY): Marcel Dekker, 2007: 333
68. Tabrizi MA, Tseng CL, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11 (1-2): 81-88
69. Mortensen DL, Walicke PA, Wang X, et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 2005; 45 (3): 286-298
70. Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62 (5): 779-786
71. Loegering DJ, Blumenstock FA, Cuddy BG. Determination of Kupffer cell Fc receptor function in vivo following injury. Proc Soc Exp Biol Med 1989; 192 (3): 255-260
72. Karanikas G, Ulrich-Pur H, Becherer A, et al. Uptake of indium-111-labeled human polyclonal immunoglobulin G in pancreatic cancer: in vivo and in vitro studies. Oncol Rep 2002; 9 (2): 353-357
73. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999; 288 (1): 371-378
74. Supersaxo A, Hein WR, SteffenH. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990; 7 (2): 167-169
75. Porter CJ, CharmanWN. Transport and absorption of drugs via the lymphatic system. Adv Drug Deliv Rev 2001; 50 (1-2): 1-2
76. Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000; 89 (3): 297-310
77. Dayneka NL, Garg V, JuskoWJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21 (4): 457-478
78. Modi NB. Recombinant thrombolytic agents. In: Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical biotechnology: fundamentals and applications. 3rd ed. New York (NY): Marcel Dekker, 2007: 326-328
79. Mould DR, Davis CB, Minthorn EA, et al. Population pharmacokinetic/ pharmacodynamic analysis of the effects of Clenoliximab, a PRIMATIZED™ anti-CD4 monoclonal antibody, on T lymphocytes, following single doses to patients with active rheumatoid arthritis. Clin Pharmacol Ther 1999; 66 (3): 246-257
80. Krzyzanski W, Jusko WJ. Integrated functions for four basic models of indirect pharmacodynamic response. J Pharm Sci 1998; 87 (1): 67-72 (Pubitemid 28079263)
81. Muller PY, Brennan FR. Safety assessment and dose selection for firstin- human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 2009; 85 (3): 247-258
82. Dayan CM, Wraith DC. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412. Clin Exp Immunol 2008; 151 (2): 231-234
83. Food and Drug Administration. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers [online]. Available from URL: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm078932.pdf [Accessed 2009 Sep 4]
84. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44 (10): 1051-1065
85. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-332
86. Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82 (5): 505-508
87. Wang B, Roskos L. The utility of trial simulation to investigate dosing strategy. AAPS 2004 Annual Meeting [online]. Available from URL: http:// www.aapspharmaceutica.com/inside/focus-groups/ModelSim/imagespdfs/ 04Wang.pdf [Accessed 2009 Sep 4]
88. Wang DD, Shuzhong Z, Zhao H, et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult trials. J Clin Pharmacol 2009; 49: 1012-1024
89. Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007 Apr; 62 (1): 43-52
90. Maloney DG, Grillo-Ló pez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patientswith relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195
91. Roy A, Mould DR, Wang XF, et al. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol 2007; 47 (11): 1408-1420
92. Joshi A, Bauer R, Kuebler P, et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol 2006; 46 (1): 10-20
93. Leyland-Jones B, Colomer R, Trudeau ME, et al. Effect of an intensive trastuzumab loading regimen on early serum concentrations. 2007 ASCO Breast Cancer Symposium [online]. Available fromURL: http://www.asco. org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail-view&confID= 52&abs tractID=40313 [Accessed 2009 Sep 4]
94. Food and Drug Administration. Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling [online]. Available from URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf [Accessed 2009 Sep 4]
95. Mahmood I, Green MD. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol 2007; 47: 1540-1554
96. Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol 2007; 47: 1104-1118
97. Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov Today 2009; 14: 891-898
98. Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007; 12: 540-547
99. Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines downregulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707-715
100. Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 2001; 29 (3): 207-212
101. Strehlau J, Pape L, Offner G, et al. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 2000; 356: 1327-1328
102. Vasquez EM, Pollak R. OKT3 therapy increases cyclosporine blood levels. Clin Transplant 1997; 11: 38-41
103. Sifontis NM, Benedetti E, Vasquez EM. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc 2002; 34: 1730-1732
104. Bunescu A, Seideman P, Lenkei R, et al. Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 2004; 31: 2347-2355
105. Höcker B, Kovarik JM, Daniel V, et al. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation 2008 15; 86 (9): 1234-1240
106. Approved prescribing information for Herceptin (trastuzumab) [data on file]. San Francisco (CA): Genentech Inc., 2008 Jan
107. Diéras V, Beuzeboc P, Laurence V, et al. Interaction between Herceptin and taxanes. Oncology 2001; 61 Suppl. 2: 43-49
108. Henson ES, Hu X, Gibson SB. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 2006 1; 12 (3 Pt 1): 845-853
109. Shah DK, Shin BS, Veith J, et al. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther 2009; 329 (2): 580-591
110. RoseWC,Wild R. Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts. Clin Cancer Res 2004 1; 10 (21): 7413-7417
111. Inoue K, Slaton J, Perrotte P, et al. Paclitaxel enhances the effects of the antiepidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2006; 6: 4874-4884
112. Huang S, Armstrong EA, Benavente S, et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64: 5355-5362
113. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) [abstract]. Proc Am Soc Clin Oncol 2003; 22: 252
114. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc Am Soc Clin Oncol 2001; 20: 3
115. Sharpe AH, Abbas AK. T-cell costimulation: biology, therapeutic potential, and challenges. N Eng J Med 2006; 355: 973-975
116. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Eng JMed 2006; 355: 1018-1028
117. Stüve O, Gold R, Chan A, et al. Alpha4-Integrin antagonism with natalizumab: effects and adverse effects. J Neurol 2008; 255 Suppl. 6: 58-65